Literature DB >> 34133717

Prostate cancer-associated SPOP mutations lead to genomic instability through disruption of the SPOP-HIPK2 axis.

Xiaofeng Jin1,2, Shi Qing3, Qian Li1,2, Hui Zhuang1,2, Liliang Shen4, Jinhui Li1, Honggang Qi5, Ting Lin1,2, Zihan Lin1,2, Jian Wang1,2, Xinyi Cao1,2, Jianye Yang1,2, Qi Ma6, Linghua Cong4, Yang Xi2, Shuai Fang2, Xiaodan Meng2, Zhaohui Gong2, Meng Ye1,2, Shuyun Wang7, Chenji Wang3, Kun Gao8.   

Abstract

Speckle-type Poz protein (SPOP), an E3 ubiquitin ligase adaptor, is the most frequently mutated gene in prostate cancer. The SPOP-mutated subtype of prostate cancer shows high genomic instability, but the underlying mechanisms causing this phenotype are still largely unknown. Here, we report that upon DNA damage, SPOP is phosphorylated at Ser119 by the ATM serine/threonine kinase, which potentiates the binding of SPOP to homeodomain-interacting protein kinase 2 (HIPK2), resulting in a nondegradative ubiquitination of HIPK2. This modification subsequently increases the phosphorylation activity of HIPK2 toward HP1γ, and then promotes the dissociation of HP1γ from trimethylated (Lys9) histone H3 (H3K9me3) to initiate DNA damage repair. Moreover, the effect of SPOP on the HIPK2-HP1γ axis is abrogated by prostate cancer-associated SPOP mutations. Our findings provide new insights into the molecular mechanism of SPOP mutations-driven genomic instability in prostate cancer.
© The Author(s) 2021. Published by Oxford University Press on behalf of Nucleic Acids Research.

Entities:  

Year:  2021        PMID: 34133717     DOI: 10.1093/nar/gkab489

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  3 in total

1.  CircHIPK2 promotes proliferation of nasopharyngeal carcinoma by down-regulating HIPK2.

Authors:  Dan Zhang; Haiping Huang; Yangguang Sun; Fuwei Cheng; Shuangping Zhao; Jisheng Liu; Peng Sun
Journal:  Transl Cancer Res       Date:  2022-07       Impact factor: 0.496

2.  ERK1/2 inhibits Cullin 3/SPOP-mediated PrLZ ubiquitination and degradation to modulate prostate cancer progression.

Authors:  Yizeng Fan; Tao Hou; Weichao Dan; Yasheng Zhu; Bo Liu; Yi Wei; Zixi Wang; Yang Gao; Jin Zeng; Lei Li
Journal:  Cell Death Differ       Date:  2022-02-22       Impact factor: 12.067

3.  Comprehensive analysis of TP53 and SPOP mutations and their impact on survival in metastatic prostate cancer.

Authors:  Jie Zhou; Yiming Lai; Shengmeng Peng; Chen Tang; Yongming Chen; Lingfeng Li; Hai Huang; Zhenghui Guo
Journal:  Front Oncol       Date:  2022-08-31       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.